The Cheshire and Merseyside Area Prescribing Group recommends the prescribing of DAPAGLIFLOZIN and EMPAGLIFLOZIN, following specialist recommendation, as options for treating symptomatic chronic heart failure with reduced ejection fraction in accordance with NICE TA679 and NICE TA773, and symptomatic chronic heart failure with preserved or mildly reduced ejection fraction, in accordance with NICE TA902 and TA929.
